Migraine Headache clinical trials

Explore recruiting migraine headache clinical trials.

Recruiting migraine headache studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Migraine Headache trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Finland, Germany, Sweden, Austria, Belgium, France +4 more

Therapeutic use (Phase IV) EU CTIS Study details

I5Q-MC-CGAS: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study

Denmark, Spain, Italy, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

I5Q-MC-CGAT:A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study

Denmark, Spain, France, Netherlands, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

ASIC Channels and Migraine Disease - Proof-of-Concept Study on the Efficacy of Amiloride in Migraine Aura Prophylaxis

France

Phase II and Phase III (Integrated) EU CTIS Study details

MiBlock - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic migraine

Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine

Czechia, Poland, Netherlands, Italy, Hungary, Spain +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Migraine Headache trials by city

Migraine Headache in Toronto Migraine Headache in Vancouver Migraine Headache in Montreal Migraine Headache in Calgary Migraine Headache in Edmonton Migraine Headache in Ottawa Migraine Headache in Winnipeg Migraine Headache in Quebec City Migraine Headache in Hamilton Migraine Headache in Kitchener Migraine Headache in London Migraine Headache in Halifax Migraine Headache in New York Migraine Headache in Los Angeles Migraine Headache in Chicago Migraine Headache in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease